In October TV pharma ad spending, AbbVie's Humira and Pfizer's Lyrica continue to dominate

AbbVie HQ

No October surprise here. AbbVie’s Humira is once again the top-spending TV pharma advertiser for the month. However, maybe just a little surprising is that its spending of $39.1 million was up 85% year-over-year from last October’s list-topping $21.1 million, according to data from real-time TV ad tracker iSpot.tv.

AbbVie has been spending aggressively for Humira on TV and in overall advertising for the past several years, in whats seems to be a lead-up to the drug's U.S. patent expiration at the end of this year. Not that the drugmaker is folding without a fight. AbbVie has already struck back at Humira’s first approved biosimilar competitor, filing a patent infringement lawsuit against Amgen in August.

Total TV spending for all the pharma ads in the top 10 this month was $193 million, a 62% jump over last month’s total of $140 million.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

Two newcomers to the top group came in at the bottom on the chart--Nos. 9 and 10, both Eli Lilly drugs. At No. 9 is its new psoriasis fighter Taltz, with a TV campaign that launched in October. At No. 10 is diabetes treatment Trulicity, with new TV creative that continues the theme of the first TV campaign launched a year ago.

 

1. Humira

Movement: Stayed the same

What is it? AbbVie anti-inflammatory drug

Total estimated spending: $39.1M (up from $32.3M in Sept.)

Number of spots: 7 (2 for arthritis, 3 for ulcerative colitis/Crohn's, 2 for psoriasis)

Biggest-ticket ad: "Go further” for arthritis (est. $12 M)

 

  <div style="position:relative;width:100%;padding-top:56.25%;padding-bottom:40px;"><iframe style="position:absolute;top:0;right:0;left:0;bottom:0;width:100%;height:100%;" src="https://www.ispot.tv/share/ATk7" frameborder="0" scrolling="no" allowfullscreen=""></iframe></div>

 

2. Lyrica

Movement: Stayed the same

What is it? Pfizer seizure and pain drug

Total estimated spending: $29.6M (up from $21.4M in Sept.)

Number of spots: 6

Biggest-ticket ad: "Keep the Beat Going" (est. $12.2M)

 

<div style="position:relative;width:100%;padding-top:56.25%;padding-bottom:40px;"><iframe style="position:absolute;top:0;right:0;left:0;bottom:0;width:100%;height:100%;" src="https://www.ispot.tv/share/A1ak" frameborder="0" scrolling="no" allowfullscreen=""></iframe></div>

 

3. Eliquis

Movement: Up from No. 8

What is it? Pfizer and Bristol-Myers Squibb anticoagulant

Total estimated spending: $20.8M (up from $10.5M in Sept.)

Number of spots: 2

Biggest-ticket ad: "Fisherman” (est. $15.9M)

 

<div style="position:relative;width:100%;padding-top:56.25%;padding-bottom:40px;"><iframe style="position:absolute;top:0;right:0;left:0;bottom:0;width:100%;height:100%;" src="https://www.ispot.tv/share/AMeG" frameborder="0" scrolling="no" allowfullscreen=""></iframe></div>

 

4. Latuda

Movement: Stayed the same

What is it? Sunovion Pharmaceutical anti-psychotic

Total estimated spending $18.1M (up from $15.9M in Sept.)

Number of spots: 2

Biggest-ticket ad: "Maya's Story" (est. $13.4M)

 

<div style="position:relative;width:100%;padding-top:56.25%;padding-bottom:40px;"><iframe style="position:absolute;top:0;right:0;left:0;bottom:0;width:100%;height:100%;" src="https://www.ispot.tv/share/ANW0" frameborder="0" scrolling="no" allowfullscreen=""></iframe></div>

 

5. Cialis
Movement: Stayed the same
What is it? Eli Lilly erectile dysfuntion treatment
Total estimated spending: $17.84M (up from $11.8M in Sept.)
Number of spots: 3


Biggest-ticket ad: "A Moment Turns Romantic" (est. $16.2 million)

 <div style="position:relative;width:100%;padding-top:56.25%;padding-bottom:40px;"><iframe style="position:absolute;top:0;right:0;left:0;bottom:0;width:100%;height:100%;" src="https://www.ispot.tv/share/ANaP" frameborder="0" scrolling="no" allowfullscreen=""></iframe></div>

 

6. Viagra
Movement: Up from No. 9
What is it? Pfizer erectile dysfunction treatment
Total estimated spending: $17.80M (up from $10.1M in Sept.)
Number of spots: 3
Biggest-ticket ad: "Single Packs: Overpack" (est. $9.9M)

 

<div style="position:relative;width:100%;padding-top:56.25%;padding-bottom:40px;"><iframe style="position:absolute;top:0;right:0;left:0;bottom:0;width:100%;height:100%;" src="https://www.ispot.tv/share/AjJs" frameborder="0" scrolling="no" allowfullscreen=""></iframe></div>

 

7. Invokana
Movement: Down from No. 3
What is it? J&J’s SGLT2 diabetes drug
Total estimated spending: $16.1M (down from $17.8M in Sept.)
Ad: “Turn Things Around”

 

<div style="position:relative;width:100%;padding-top:56.25%;padding-bottom:40px;"><iframe style="position:absolute;top:0;right:0;left:0;bottom:0;width:100%;height:100%;" src="https://www.ispot.tv/share/AGMe" frameborder="0" scrolling="no" allowfullscreen=""></iframe></div>

 

8. Xeljanz XR
Movement: Down from No. 5
What is it? Pfizer’s second-line, oral rheumatoid arthritis therapy
Total estimated spending: $14.3M (up from $11.2M in Sept.)
Number of spots: 2
Biggest-ticket Ad: "Better Things” (est. $10.4M)

 

<div style="position:relative;width:100%;padding-top:56.25%;padding-bottom:40px;"><iframe style="position:absolute;top:0;right:0;left:0;bottom:0;width:100%;height:100%;" src="https://www.ispot.tv/share/AMAy" frameborder="0" scrolling="no" allowfullscreen=""></iframe></div>

 

9. Taltz

Movement: Not in top 10 last month

What is it? Eli Lilly’s IL-17A psoriasis treatment

Total estimated spending $10.1M

Number of spots: 3

Biggest-ticket ad: “Close to the People You Love” (est. $6.5M)

 

<div style="position:relative;width:100%;padding-top:56.25%;padding-bottom:40px;"><iframe style="position:absolute;top:0;right:0;left:0;bottom:0;width:100%;height:100%;" src="https://www.ispot.tv/share/ANXn" frameborder="0" scrolling="no" allowfullscreen=""></iframe></div>

 

10. Trulicity

Movement: Not in top 10 last month

What is it?  Eli Lilly’s GLP-1 diabetes drug

Total estimated spending $9.1M

Number of spots: 2

Biggest-ticket ad: “Restoration” (est. $5.1M)

 

<div style="position:relative;width:100%;padding-top:56.25%;padding-bottom:40px;"><iframe style="position:absolute;top:0;right:0;left:0;bottom:0;width:100%;height:100%;" src="https://www.ispot.tv/share/AM8p" frameborder="0" scrolling="no" allowfullscreen=""></iframe></div>

 

Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

Kinase inhibitors to treat cancer have driven nearly $100 billion in deals since 2010, a trend that's likely to grow, SVB Leerink analysts predict.